Amgen (NQ:AMGN)

There is an even more important question to address.

Topics Intellectual Property

Can These Dividend Stocks Beat the Market Again in 2026? ↗

January 08, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Topics Artificial Intelligence Economy Intellectual Property

Why Is ZBIO Stock Falling Pre-Market Today? ↗

January 06, 2026

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Topics Economy

1 S&P 500 Stock with Exciting Potential and 2 We Question

January 04, 2026

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

Topics Stocks

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

As the calendar turns to January 2, 2026, the investment landscape is undergoing a tectonic shift. After years of dominance by mega-cap technology giants, the "Great Rotation" has finally reached the...

Topics Economy Intellectual Property World Trade

The Rise of the 'Dividogs': Small-Cap Yield Kings Poised to Lead the 2026 Market Rotation

January 02, 2026

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

Topics Artificial Intelligence Economy Stocks

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Topics Economy Intellectual Property

1 Safe-and-Steady Stock to Keep an Eye On and 2 We Question

December 30, 2025

Amgen’s 17.6% return over the past six months has outpaced the S&P 500 by 6.3%, and its stock price has climbed to $328.43 per share. This was partly due to its solid quarterly results, and the...

Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings?

December 30, 2025

As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of...

Topics Stocks

The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance

December 29, 2025

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...

Topics Earnings Economy Intellectual Property

3 Profitable Stocks with Competitive Advantages

December 28, 2025

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

December 25, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

Topics Artificial Intelligence Economy Intellectual Property

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics Economy Intellectual Property World Trade

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine

Topics Economy Government Intellectual Property

December 24, 2025

In a milestone that many scientists once considered a "pipe dream" for the next decade, researchers at the University of Washington’s (UW) Institute for Protein Design (IPD) announced in late 2025 the...

Via TokenRing AI

Topics Artificial Intelligence

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

December 24, 2025

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

Topics Economy

December 23, 2025

Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency

Topics Government

SCHD vs. NOBL: Different Paths to Dividend Stability ↗

December 22, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.

Topics ETFs

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

December 21, 2025

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics Artificial Intelligence

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

As the final weeks of 2025 unfold, the biotechnology sector is undergoing a fundamental transformation, shifting from a pure-play innovation market to one increasingly dictated by the "physical"...

Topics Government World Trade

The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era

December 19, 2025

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

Topics Earnings Economy Intellectual Property

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

As late 2025 draws to a close, a significant recalibration is underway in global financial markets, with investors increasingly rotating capital away from the once-dominant Big Tech and Artificial...

Topics Artificial Intelligence ETFs Economy

Investors Rotate Out of Big Tech and AI: A Market Reassessment Underway

December 17, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

Topics Artificial Intelligence Economy Stocks

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Each company has a bullish case, but three stand out as great long-term buys.

Topics Government World Trade

Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? ↗

December 16, 2025

“Buying the Dip” in 2025: A Strategy Rewarded, But Future Requires Caution and Diversification

Topics Bonds Economy Intellectual Property

December 16, 2025

December 16, 2025 – The "buying the dip" investment strategy, which involves purchasing an asset after its price has declined with the anticipation of a subsequent recovery, has seen significant...

7 Dividend ETFs to Buy With $2,000 and Hold Forever -- Including the Schwab U.S. Dividend Equity ETF (SCHD) ↗

Topics Artificial Intelligence Economy

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most ↗

December 16, 2025

Via MarketBeat

December 15, 2025

It's hard to beat dividend-paying stocks -- in part because they tend to increase their payouts regularly.